Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
 SummaryChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
03/25/2020 03/26/2020 03/27/2020 03/30/2020 03/31/2020 Date
13.85 14.44 13.98 14.55 14.42 Last
1849173 1510712 1006961 1471412 1413928 Volume
+0.14% +4.26% -3.19% +4.08% -0.89% Change
Company
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT.... 
More about the company
Ratings of Aimmune Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about AIMMUNE THERAPEUTICS, INC.
06/08Aimmune Therapeutics Launches the First Real-World Registry Study for Patient..
CI
02/25Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Th..
CI
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
01/05AIMMUNE THERAPEUTICS : European Commission approves first treatment for peanut a..
AQ
2020AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
2020AIMMUNE THERAPEUTICS : European Commission Approves Aimmune's PALFORZIA« as Firs..
BU
2020European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for ..
CI
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
2020Aimmune Therapeutics, Inc. Announces Executive Changes
CI
2020AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
2020Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA« for t..
CI
2020MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
2020AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
More news
News in other languages on AIMMUNE THERAPEUTICS, INC.
2020Bourse Zurich: la nouvelle variante du coronavirus effraie le marché
2020Bourse Zurich: toujours plombée par les craintes sur la nouvelle souche de vi..
2020Bourse Zurich: les craintes sur la nouvelle souche de virus l'emportent
2020Nestlé fait une percée pour traiter l'allergie aux arachides
2020Bourse Zurich: la mutation du coronavirus effraie les investisseurs
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | AIMT | US00900T1079 | MarketScreener
Managers and Directors
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
GrÚgory Behar Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.18.31%86 563
BIONTECH SE248.38%69 138
WUXI APPTEC CO., LTD.28.80%67 035
REGENERON PHARMACEUTICALS20.26%59 833
VERTEX PHARMACEUTICALS-14.17%51 496